BACKGROUND: Cysteine-rich angiogenic inducer 61 (Cyr61) is an extracellular matrix protein involved in the transduction of growth factor and hormone signaling. Previously, we demonstrated that Cyr61 was highly expressed in prostate cancer (PCa) but that the expression levels were associated with a lower risk of PCa recurrence. In the present study, we demonstrate that serum Cyr61 is a potential biomarker that correlates with PCa aggressiveness. Furthermore, we also explore the potential mechanism underlying the changes in Cyr61 expression during PCa progression. METHODS: Cyr61 concentrations in the medium from PCa cell lines and in serum samples obtained from PCa patients were measured by sandwich ELISA. Serum Cyr61 levels were correlated with disease characteristics and the association between Cyr61 expression changes by several types of stimulation or stress and cAMP/cAMP-dependent protein kinase (PKA) pathway were examined. RESULTS: There was a positive correlation between Cyr61 levels in cell supernatants and mRNA expression in these cell lines. Serum Cyr61 levels were significantly higher in non-organ-confined PCa patients (116.3 ± 140.2 ng/ml) than in organ-confined PCa patients (79.7 ± 56.1 ng/ml) (P = 0.031). Cyr61 expression was up-regulated in response to both lysophosphatidic acid and androgen treatments which promoted PCa cell invasion. Serum starvation and phosphoinositide-3-kinase inhibition also resulted in Cyr61 up-regulation; however, they suppressed cell proliferation. Cyr61 up-regulation was correlated with an increase in cAMP and suppressed by PKA inhibition. CONCLUSIONS: These findings suggest that Cyr61 expression in PCa is regulated by the cAMP/PKA pathway and that circulating Cyr61 levels are a potential serum-based biomarker for characterizing PCa.
BACKGROUND:Cysteine-rich angiogenic inducer 61 (Cyr61) is an extracellular matrix protein involved in the transduction of growth factor and hormone signaling. Previously, we demonstrated that Cyr61 was highly expressed in prostate cancer (PCa) but that the expression levels were associated with a lower risk of PCa recurrence. In the present study, we demonstrate that serum Cyr61 is a potential biomarker that correlates with PCa aggressiveness. Furthermore, we also explore the potential mechanism underlying the changes in Cyr61 expression during PCa progression. METHODS:Cyr61 concentrations in the medium from PCa cell lines and in serum samples obtained from PCa patients were measured by sandwich ELISA. Serum Cyr61 levels were correlated with disease characteristics and the association between Cyr61 expression changes by several types of stimulation or stress and cAMP/cAMP-dependent protein kinase (PKA) pathway were examined. RESULTS: There was a positive correlation between Cyr61 levels in cell supernatants and mRNA expression in these cell lines. Serum Cyr61 levels were significantly higher in non-organ-confined PCa patients (116.3 ± 140.2 ng/ml) than in organ-confined PCa patients (79.7 ± 56.1 ng/ml) (P = 0.031). Cyr61 expression was up-regulated in response to both lysophosphatidic acid and androgen treatments which promoted PCa cell invasion. Serum starvation and phosphoinositide-3-kinase inhibition also resulted in Cyr61 up-regulation; however, they suppressed cell proliferation. Cyr61 up-regulation was correlated with an increase in cAMP and suppressed by PKA inhibition. CONCLUSIONS: These findings suggest that Cyr61 expression in PCa is regulated by the cAMP/PKA pathway and that circulating Cyr61 levels are a potential serum-based biomarker for characterizing PCa.
Authors: Elizabeth A Kasbohm; Rishu Guo; Charles W Yowell; Gargi Bagchi; Patrick Kelly; Puneeta Arora; Patrick J Casey; Yehia Daaka Journal: J Biol Chem Date: 2005-01-14 Impact factor: 5.157
Authors: Shane E Holloway; Adam W Beck; Luc Girard; M Raffat Jaber; Carlton C Barnett; Rolf A Brekken; Jason B Fleming Journal: J Am Coll Surg Date: 2005-03 Impact factor: 6.113
Authors: C P Pilarsky; U Schmidt; C Eissrich; J Stade; S E Froschermaier; M Haase; G Faller; T W Kirchner; M P Wirth Journal: Prostate Date: 1998-07-01 Impact factor: 4.104
Authors: Krithika Rajagopalan; Ruoyi Qiu; Steven M Mooney; Shweta Rao; Takumi Shiraishi; Elizabeth Sacho; Hongying Huang; Ellen Shapiro; Keith R Weninger; Prakash Kulkarni Journal: Biochim Biophys Acta Date: 2013-11-18
Authors: Siddik Sarkar; Bridget A Quinn; Xue-Ning Shen; Rupesh Dash; Swadesh K Das; Luni Emdad; Alexander L Klibanov; Xiang-Yang Wang; Maurizio Pellecchia; Devanand Sarkar; Paul B Fisher Journal: Oncotarget Date: 2015-05-10
Authors: Joana Cardoso; Marta Mesquita; António Dias Pereira; Mónica Bettencourt-Dias; Paula Chaves; José B Pereira-Leal Journal: PLoS One Date: 2016-09-01 Impact factor: 3.240
Authors: Mitsuaki Ono; Colette A Inkson; Robert Sonn; Tina M Kilts; Luis F de Castro; Azusa Maeda; Larry W Fisher; Pamela G Robey; Agnes D Berendsen; Li Li; Nancy McCartney-Francis; Aaron C Brown; Nigel P S Crawford; Alfredo Molinolo; Alka Jain; Neal S Fedarko; Marian F Young Journal: PLoS One Date: 2013-08-14 Impact factor: 3.240
Authors: Steven M Mooney; Ruoyi Qiu; John J Kim; Elizabeth J Sacho; Krithika Rajagopalan; Dorhyun Johng; Takumi Shiraishi; Prakash Kulkarni; Keith R Weninger Journal: Biochemistry Date: 2014-03-05 Impact factor: 3.162